(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 31 August 2000 (31.08.2000)

PCT

(10) International Publication Number WO 00/50075 A3

- (51) International Patent Classification⁷: A61K 39/095, 39/39, A61P 31/04 // C12N 15/31, C07K 14/22
- (21) International Application Number: PCT/IB00/00176
- (22) International Filing Date: 9 February 2000 (09.02.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: 60/121,792 26 February 1999 (26.02.1999) US
- (71) Applicant (for all designated States except US): CHIRON S.P.A. [IT/IT]; Instituto Ricerche Immunobiologiche, Via Fiorentina, 1, I-53100 Siena (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRANDI, Guido [IT/IT]; Chiron S.p.A., Instituto Ricerche Immunobiologiche, Via Fiorentina, 1, I-53100 Siena (IT). RAP-PUOLI, Rino [IT/IT]; Chiron S.p.A., Instituto Ricerche Immunobiologiche, Via Fiorentina, 1, I-53100 Siena (IT). GIULIANI, Marzia, Monica [IT/IT]; Chiron S.p.A., Instituto Ricerche Immunobiologiche, Via Fiorentina, 1, I-53100 Siena (IT). PIZZA, Mariagrazia [IT/IT]; Chiron S.p.A., Instituto Ricerche Immunobiologiche, Via Fiorentina, 1, I-53100 Siena (IT).

- (74) Agents: HALLYBONE, Huw, George et al.; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU; ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- (88) Date of publication of the international search report: 11 January 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ENHANCEMENT OF BACTERICIDAL ACTIVITY OF NEISSERIA ANTIGENS WITH OLIGONUCLEOTIDES CONTAINING CG MOTIFS

(57) Abstract: Immunogenic compositions (e.g. vaccines) comprising: (a) an immunostimulating amount of a Neisseria antigen (preferably N. meningitidis serogroup B); and (b) an immunostimulating amount of an adjuvant composition comprising an oligonucleotide comprising at least one CG motif. Component (b) may further comprise a second adjuvant. Component (a) may be selected from a variety of antigens. Adjuvant compositions comprising an oligonucleotide having at least one CG motif, and complete Freund's adjuvant (CFA) are also provided.





PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification of (Form PCT/ISA/2	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.			
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/IB 00/00176	09/02/2000	26/02/1999			
Applicant					
CHIRON S.P.A. et al.					
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Auth Insmitted to the International Bureau.	nority and is transmitted to the applicant			
This International Search Report consists X	of a total of <u>5</u> sheets. a copy of each prior art document cited in this	report.			
1. Basis of the report					
With regard to the language, the insurance language in which it was filed, unless	nternational search was carried out on the bas ess otherwise indicated under this item.	sis of the international application in the			
the international search was Authority (Rule 23.1(b)).	as carried out on the basis of a translation of th	ne international application furnished to this			
was carried out on the basis of the	d/or amino acid sequence disclosed in the insequence listing: nal application in written form.	ternational application, the international search			
<u> </u>	national application in computer readable form	1.			
	this Authority in written form.				
r oz ri	this Authority in computer readble form.	•			
the statement that the subsinternational application as					
the statement that the infor furnished	mation recorded in computer readable form is	identical to the written sequence listing has been			
2. X Certain claims were foun	d unsearchable (See Box I).				
3. X Unity of Invention is lack	ing (see Box II).				
4. With regard to the title,					
X the text is approved as sub	mitted by the applicant.				
the text has been established	ed by this Authority to read as follows:				
5. With regard to the abstract , the text is approved as sublimate the text has been established within one month from the control of the c	mitted by the applicant. ed, according to Rule 38.2(b), by this Authority date of mailing of this international search repo	y as it appears in Box III. The applicant may,			
6. The figure of the drawings to be publish		or, submit comments to this Authority.			
as suggested by the applica	-	None of the figures			
because the applicant failed		None of the figures.			
because this figure better ch					



ational application No. PCT/IB 00/00176

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet) Immunogenic compositions (e.g.vaccines) comprising: (a) an immunostimulating amount of a Neisseria antigen (preferably N. meningitidis serogroup B); and (b) an immunostimulating amount of an adjuvant composition comprising an oligonucleotide comprising at least one CG motif. Component (b) may further comprise a second adjuvant. Component (a) may be selected from a variety of antigens. Adjuvant compositions comprising an oligonucleotide having at least one CG motif, and complete Freund's adjuvant (CFA) are also provided.





Relevant to claim No.

1-4

18-21,

a. classification of subject matter IPC 7 A61K39/095 A61K39/39

C. DOCUMENTS CONSIDERED TO BE RELEVANT

A61P31/04

//C12N15/31,C07K14/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Category °

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

STRAND, MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ

JOEL N (US); KRIEG ARTHUR M (US))

Citation of document, with indication, where appropriate, of the relevant passages

WO 98 18810 A (UNIV IOWA RES FOUND ; KLINE

		7 May 1998 (1998-05-07) page 11, line 12 page 10, line 16-23 page 17, line 8,9 page 27, line 23	·	23, 32-37, 40-42
L	<i>X</i> -	claims 23,26 WO 98 49288 A (HYBRIDON INC) 5 November 1998 (1998-11-05) page 4, paragraph 2 page 12, paragraph 2		1-4, 18-21, 23, 32-37, 40-42
		ner documents are listed in the continuation of box C.	Patent family members are listed "T" later document published after the inte	
	"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means		or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
	later th	nt published prior to the international filing date but an the priority date claimed actual completion of the international search	"&" document member of the same patent Date of mailing of the international sea	
	4	October 2000	17/10/2000	
	Name and m	nailing address of the ISA	Authorized officer	

1

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

Covone, M



	PC1/18 00/001/6
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
WO 98 55495 A (DYNAVAX TECHNOLOGIES CORP; DINA DINO (US); ROMAN MARK (US); SCHWAR) 10 December 1998 (1998-12-10) page 15, line 5-25 examples 1,2 claim 23	27-31, 40,41
SUN SIQUAN ET AL: "DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 7, 6 April 1998 (1998-04-06), pages 1145-1150, XP002148907 ISSN: 0022-1007 abstract page 1146, left-hand column, line 1-5 -right-hand column, line 5-10	6-17,24, 27
MILLAN CYNTHIA L BRAZOLOT ET AL: "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 26, 22 December 1998 (1998-12-22), pages 15553-15558, XP002148908 Dec. 22, 1998 ISSN: 0027-8424 abstract figure 2	6-17,24,
WO 99 58683 A (RUELLE JEAN LOUIS; SMITHKLINE BEECHAM BIOLOG (BE)) 18 November 1999 (1999-11-18) cited in the application page 31, line 14 -page 36, line 24	1-4,6, 18,20, 22-24, 26, 32-37, 40-42
WO 99 57280 A (PIZZA MARIAGRATIA ; MORA MARIROSA (IT); RAPPUOLI RINO (IT); GALEOTT) 11 November 1999 (1999-11-11) cited in the application page 135 example 15	5,25,38
	;DINA DINO (US); ROMAN MARK (US); SCHWAR) 10 December 1998 (1998-12-10) page 15, line 5-25 examples 1,2 claim 23 SUN SIQUAN ET AL: "DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 7, 6 April 1998 (1998-04-06), pages 1145-1150, XP002148907 ISSN: 0022-1007 abstract page 1146, left-hand column, line 1-5 -right-hand column, line 5-10 MILLAN CYNTHIA L BRAZOLOT ET AL: "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 26, 22 December 1998 (1998-12-22), pages 15553-15558, XP002148908 Dec. 22, 1998 ISSN: 0027-8424 abstract figure 2 WO 99 58683 A (RUELLE JEAN LOUIS ;SMITHKLINE BEECHAM BIOLOG (BE)) 18 November 1999 (1999-11-18) cited in the application page 31, line 14 -page 36, line 24 WO 99 57280 A (PIZZA MARIAGRATIA ;MORA MARIROSA (IT); RAPPUOLI RINO (IT); GALEOTT) 11 November 1999 (1999-11-11) cited in the application

1



This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-26 32-39 (all completely) 40-42 (all partially)

An immunogenic composition comprising a Neisseria antigen and an adjuvant composition comprising an oligonucleotide comprising at least one CG motif and, optionally, a second adjuvant.

2. Claims: 27-31 (all completely) 40-42 (all partially)

An adjuvant composition comprising at least one CG motif and complete Freund's adjuvant and any antigen other then Neisseria





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 32-39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. X	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

Patent document cited in search repo		Publication date		Patent family member(s)	Publication date
WO 9818810	Α	07-05-1998	AU CN EP	5242498 A 1235609 A 0948510 A	22-05-1998 17-11-1999 13-10-1999
WO 9849288	A ·	05-11-1998	AU EP	7171298 A 0991755 A	24-11-1998 12-04-2000
WO 9855495	A	10-12-1998	AU AU EP EP WO	7811398 A 7817898 A 1003850 A 0986572 A 9855609 A	21-12-1998 21-12-1998 31-05-2000 22-03-2000 10-12-1998
WO 9958683	A	18-11-1999	AU	4142099 A	29-11-1999
WO 9957280	Α	11-11-1999	AU	3967799 A	23-11-1999